Saturday 17 October 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.09
0.18
−5.50%
Follow ARDX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 6 | 5 | 3 | 3 | 3 | 2 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 10.94 | 38.60 | 90.24 | 76.55 | 11.35 | 8.15 | 10.66 | 3.57 | 3.45 |
Altman Z-Score |
— | 7.54 | (2.48) | 1.41 | 0.30 | (8.32) | (3.07) | 2.76 | 1.20 | 1.12 |
Altman Z″-Score (non-manufacturers) |
— | 4.83 | (2.36) | 0.35 | (4.83) | (17.60) | (11.47) | (5.05) | (2.17) | (2.34) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | 1.37 | (2.17) | — | — | 3.66 | (0.58) | (1.05) | (2.40) |
P/Operating CF |
— | 70.68 | (5.46) | (43.48) | (32.95) | (2.90) | 29.77 | (152.21) | 121.57 | 67.07 |
P/B ratio |
— | 2.38 | 0.87 | 2.59 | 4.60 | 1.39 | 4.33 | 7.95 | 6.88 | 8.42 |
Price to Tangible BV |
— | 2.38 | 0.87 | 2.59 | 4.60 | 1.39 | 4.33 | 7.95 | 6.88 | 8.42 |
EV/Sales |
— | 6.52 | (7.00) | 53.44 | 58.63 | 3.96 | 6.62 | 9.80 | 3.36 | 3.36 |
EV/EBITDA |
— | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (3.04) | 0.26 | (3.75) | (5.45) | (0.26) | (4.93) | (13.59) | (25.00) | (32.26) |
EV/FCF |
— | (2.93) | 0.26 | (3.73) | (5.43) | (0.26) | (5.05) | (13.54) | (24.45) | (31.16) |
Quick Ratio |
10.46 | 8.10 | 9.77 | 11.17 | 6.56 | 2.22 | 2.01 | 4.09 | 3.95 | 3.80 |
Current Ratio |
10.62 | 8.38 | 9.95 | 11.34 | 6.85 | 2.53 | 2.34 | 4.88 | 4.58 | 4.31 |
Net Debt/EBITDA |
1.81 | 2.16 | 1.34 | 2.23 | 1.54 | 0.49 | 1.28 | 2.17 | 3.83 | 1.63 |
Debt/Assets |
0.00% | 0.00% | 26.84% | 19.25% | 25.20% | 28.02% | 23.06% | 16.74% | 34.62% | 40.44% |
Debt/Equity |
0.00 | 0.00 | 0.42 | 0.27 | 0.40 | 0.51 | 0.45 | 0.30 | 0.87 | 1.21 |
Asset Turnover |
0.00 | 0.23 | 0.02 | 0.02 | 0.03 | 0.06 | 0.31 | 0.51 | 0.91 | 0.87 |
Operating CF/Net income |
0.82 | 1.01 | 0.77 | 0.81 | 0.86 | 0.96 | 1.04 | 1.36 | 1.15 | 0.69 |
Capex/Depreciation |
(2.78) | (0.73) | (0.15) | (0.12) | (0.13) | (0.67) | 1.52 | (0.27) | (0.49) | (0.49) |
Interest Coverage |
— | — | (25.73) | (15.94) | (17.80) | (34.28) | (12.57) | (7.13) | (1.39) | (1.44) |
| (74.42%) | (38.70%) | (71.57%) | (62.78%) | (60.31%) | (151.55%) | (74.28%) | (49.83%) | (23.01%) | (36.21%) | |
| (68.10%) | (34.68%) | (53.51%) | (42.85%) | (40.89%) | (90.00%) | (39.54%) | (27.10%) | (10.67%) | (13.14%) | |
ROIC |
0.00% | (762.69%) | 0.00% | 0.00% | 0.00% | (1,214.94%) | (218.47%) | (122.29%) | (23.59%) | (24.37%) |
Return on Tangible Assets |
(58.00%) | (46.00%) | (55.58%) | (40.70%) | (56.07%) | (190.13%) | (75.32%) | (33.58%) | (13.97%) | (20.82%) |
Average Days of Receivables |
— | 93.82 | 711.94 | 51.84 | 0.00 | 18.15 | 54.12 | 64.61 | 63.13 | 64.38 |
Research and Development Expense of Revenue |
0.00% | 179.72% | 2,661.03% | 1,357.26% | 859.24% | 902.64% | 67.49% | 28.55% | 15.68% | 17.56% |
Selling, General and Administrative Expense of Revenue |
0.00% | 55.31% | 909.67% | 459.52% | 437.89% | 716.08% | 146.86% | 107.99% | 77.54% | 82.79% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 22.83% | 353.89% | 188.15% | 139.78% | 119.23% | 20.61% | 10.87% | 11.20% | 12.02% |
Graham Net Nets |
— | 0.39 | 1.08 | 0.37 | 0.21 | 0.58 | 0.15 | 0.09 | 0.08 | 0.03 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (19.43%) | (90.50%) | (19.71%) | (16.23%) | (138.18%) | (17.91%) | (4.96%) | (3.22%) | (4.36%) |
Free Cash Flow Yield |
— | (20.34%) | (70.14%) | (15.86%) | (14.11%) | (134.71%) | (16.06%) | (6.79%) | (3.84%) | (3.13%) |
Revenue per Share |
0.00 | 0.89 | 0.05 | 0.08 | 0.08 | 0.10 | 0.33 | 0.57 | 1.42 | 1.69 |
Operating CF per Share |
(2.31) | (1.37) | (1.25) | (1.19) | (0.91) | (1.46) | (0.44) | (0.41) | (0.19) | (0.18) |
Capex per Share |
(0.12) | (0.05) | (0.01) | 0.00 | 0.00 | (0.02) | 0.01 | 0.00 | 0.00 | (0.01) |
Free Cash Flow per Share |
(2.43) | (1.42) | (1.26) | (1.19) | (0.91) | (1.48) | (0.43) | (0.41) | (0.19) | (0.18) |
Cash per Share |
5.01 | 2.82 | 2.99 | 3.84 | 2.08 | 1.12 | 0.78 | 0.84 | 1.06 | 1.10 |
Shareholders Equity per Share |
4.81 | 2.94 | 2.06 | 2.89 | 1.41 | 0.79 | 0.62 | 0.76 | 0.74 | 0.69 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.81 | 2.94 | 2.06 | 2.89 | 1.41 | 0.79 | 0.62 | 0.76 | 0.74 | 0.69 |
Free Cash Flow |
(97.40) | (67.54) | (70.58) | (76.81) | (81.76) | (154.42) | (68.30) | (90.06) | (45.82) | (43.97) |
Working Capital |
184.79 | 131.84 | 158.64 | 229.84 | 166.27 | 80.83 | 88.00 | 195.72 | 278.62 | 293.71 |
Capital Expenditures |
(4.87) | (2.35) | (0.31) | (0.32) | (0.32) | (1.87) | 1.74 | (0.34) | (1.01) | (1.49) |
Net Current Asset Value |
184.01 | 131.12 | 108.85 | 178.94 | 119.24 | 66.35 | 61.87 | 115.35 | 93.99 | 47.66 |
EV/EBIT |
— | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.06 | 0.12 | 0.06 | 0.04 | 0.18 | (0.03) | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.40 | 0.36 | 0.81 | 1.31 | 1.19 | 0.94 | 1.28 | 1.38 | 1.40 |
Cash ROIC |
(24.72%) | (24.72%) | (21.19%) | (15.86%) | (22.50%) | (63.99%) | (25.67%) | (22.46%) | (7.98%) | (6.93%) |
Accounts Receivable Turnover |
— | 6.28 | 0.33 | 1.81 | 0.00 | 16.13 | 12.67 | 8.36 | 8.37 | 6.29 |
Accounts Payable Turnover |
0.31 | 1.76 | 0.18 | 0.36 | 0.04 | 0.20 | 0.54 | 1.62 | 3.73 | 2.24 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.26 | 3.01 | 2.03 |
Average Days of Payables |
1,588.24 | 170.90 | 899.18 | 1,330.43 | 14,162.00 | 1,561.11 | 962.72 | 228.46 | 115.52 | 177.57 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 290.97 | 255.33 | 152.86 | 163.73 |
Average Receivables |
— | 6.69 | 7.94 | 2.92 | — | 0.63 | 4.12 | 14.88 | 39.87 | 64.78 |
Average Payables |
4.21 | 4.78 | 2.54 | 1.67 | 3.91 | 4.95 | 7.57 | 11.00 | 13.57 | 17.62 |
Average Inventory |
— | — | — | — | — | — | — | 7.87 | 16.81 | 19.45 |
Average Assets |
165.04 | 185.52 | 170.62 | 221.56 | 230.67 | 175.74 | 169.99 | 243.82 | 366.67 | 468.68 |
Average Common Equity |
151.03 | 166.23 | 127.56 | 151.23 | 156.38 | 104.36 | 90.47 | 132.57 | 170.05 | 170.12 |
Columns are period end dates